Mangoceuticals, Inc. Common Stock (MGRX) - Total Assets
Based on the latest financial reports, Mangoceuticals, Inc. Common Stock (MGRX) holds total assets worth $16.53 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See MGRX book value for net asset value and shareholders' equity analysis.
Mangoceuticals, Inc. Common Stock - Total Assets Trend (2021–2024)
This chart illustrates how Mangoceuticals, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data.
Mangoceuticals, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2024)
Mangoceuticals, Inc. Common Stock's total assets of $16.53 Million consist of 0.5% current assets and 99.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0.4% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $15.23 Million | 99.1% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how Mangoceuticals, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Mangoceuticals, Inc. Common Stock (MGRX) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Mangoceuticals, Inc. Common Stock's current assets represent 0.5% of total assets in 2024, a decrease from 100.0% in 2021.
- Cash Position: Cash and equivalents constituted 0.4% of total assets in 2024, down from 100.0% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 99.0% of total assets, an increase from 0.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 99.1% of total assets.
Mangoceuticals, Inc. Common Stock Competitors by Total Assets
Key competitors of Mangoceuticals, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Pathkey.ai Ltd
AU:PKY
|
Australia | AU$513.28K |
|
Adheris Health Limited
AU:AHE
|
Australia | AU$39.84 Million |
|
SMAIO SA
PA:ALSMA
|
France | €14.11 Million |
|
Reliq Health Technologies Inc
V:RHT
|
Canada | CA$22.29 Million |
|
Emyria Ltd
AU:EMD
|
Australia | AU$6.62 Million |
|
Careteq Ltd
AU:CTQ
|
Australia | AU$4.44 Million |
|
Brain+ ApS
CO:BRAINP
|
Denmark | Dkr35.35 Million |
|
Tali Digital Ltd
AU:TD1
|
Australia | AU$2.77 Million |
Mangoceuticals, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.74 | 0.07 | 0.01 |
| Quick Ratio | 0.74 | 0.07 | 0.01 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-206.05K | $-1.29 Million | $-138.33K |
Mangoceuticals, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Mangoceuticals, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.37 |
| Latest Market Cap to Assets Ratio | 0.40 |
| Asset Growth Rate (YoY) | 1362.8% |
| Total Assets | $15.37 Million |
| Market Capitalization | $6.08 Million USD |
Valuation Analysis
Below Book Valuation: The market values Mangoceuticals, Inc. Common Stock's assets below their book value (0.40x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Mangoceuticals, Inc. Common Stock's assets grew by 1362.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Mangoceuticals, Inc. Common Stock (2021–2024)
The table below shows the annual total assets of Mangoceuticals, Inc. Common Stock from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $15.37 Million | +1362.75% |
| 2023-12-31 | $1.05 Million | +4.74% |
| 2022-12-31 | $1.00 Million | +4349.17% |
| 2021-12-31 | $22.55K | -- |
About Mangoceuticals, Inc. Common Stock
Mangoceuticals, Inc. engages in the development, marketing, and sale of various men's wellness products and services through a telemedicine platform in the United States. The company offers erectile dysfunction products under the Mango brand; hair loss products under the Grow brand; hormone balance and therapy products under the Mojo brand; and weight loss products under the Slim brand. It also p… Read more